Literature DB >> 24179607

Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia.

Adriana Plesa1, Youcef Chelghoum, Eve Mattei, Hélène Labussière, Mohamed Elhamri, Giovanna Cannas, Stéphane Morisset, Inès Tagoug, Mauricette Michallet, Charles Dumontet, Xavier Thomas.   

Abstract

AIM: To evaluate quantitatively and qualitatively the different CD34(+) cell subsets after priming by chemotherapy granulocyte colony-stimulating factor (± G-CSF) in patients with acute myeloid leukemia.
METHODS: Peripheral blood and bone marrow samples were harvested in 8 acute myeloid leukemia patients during and after induction chemotherapy. The CD34/CD38 cell profile was analyzed by multi-parameter flow cytometry. Adhesion profile was made using CXC chemokine receptor 4 (CXCR4) (CD184), VLA-4 (CD49d/CD29) and CD47.
RESULTS: Chemotherapy ± G-CSF mobilized immature cells (CD34(+)CD38(-) population), while the more mature cells (CD34(+)CD38(low) and CD34(+)CD38(+) populations) decreased progressively after treatment. Circulating CD34(+) cells tended to be more sensitive to chemotherapy after priming with G-CSF. CD34(+) cell mobilization was correlated with a gradual increase in CXCR4 and CD47 expression, suggesting a role in cell protection and the capacity of homing back to the marrow.
CONCLUSION: Chemotherapy ± G-CSF mobilizes into the circulation CD34(+) bone marrow cells, of which, the immature CD34(+)CD38(-) cell population. Further manipulations of these interactions may be a means with which to control the trafficking of leukemia stem cells to improve patients' outcomes.

Entities:  

Keywords:  Acute myeloid leukemia; Immunophenotype; Leukemia stem cell; Priming; Timed sequential chemotherapy

Year:  2013        PMID: 24179607      PMCID: PMC3812523          DOI: 10.4252/wjsc.v5.i4.196

Source DB:  PubMed          Journal:  World J Stem Cells        ISSN: 1948-0210            Impact factor:   5.326


  36 in total

1.  CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

Authors:  Siddhartha Jaiswal; Catriona H M Jamieson; Wendy W Pang; Christopher Y Park; Mark P Chao; Ravindra Majeti; David Traver; Nico van Rooijen; Irving L Weissman
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

2.  In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia.

Authors:  J E Karp; R C Donehower; J P Enterline; G B Dole; M G Fox; P J Burke
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

3.  Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.

Authors:  Xavier Thomas; Mohamed Elhamri; Emmanuel Raffoux; Aline Renneville; Cécile Pautas; Stéphane de Botton; Thierry de Revel; Oumedaly Reman; Christine Terré; Claude Gardin; Youcef Chelghoum; Nicolas Boissel; Bruno Quesnel; Yosr Hicheri; Jean-Henri Bourhis; Pierre Fenaux; Claude Preudhomme; Mauricette Michallet; Sylvie Castaigne; Hervé Dombret
Journal:  Blood       Date:  2011-06-20       Impact factor: 22.113

4.  Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.

Authors:  P A te Boekhorst; B Löwenberg; M Vlastuin; P Sonneveld
Journal:  Leukemia       Date:  1993-08       Impact factor: 11.528

5.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

Authors:  Fumihiko Ishikawa; Shuro Yoshida; Yoriko Saito; Atsushi Hijikata; Hiroshi Kitamura; Satoshi Tanaka; Ryu Nakamura; Toru Tanaka; Hiroko Tomiyama; Noriyuki Saito; Mitsuhiro Fukata; Toshihiro Miyamoto; Bonnie Lyons; Koichi Ohshima; Naoyuki Uchida; Shuichi Taniguchi; Osamu Ohara; Koichi Akashi; Mine Harada; Leonard D Shultz
Journal:  Nat Biotechnol       Date:  2007-10-21       Impact factor: 54.908

6.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

7.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.

Authors:  T Lapidot; C Sirard; J Vormoor; B Murdoch; T Hoang; J Caceres-Cortes; M Minden; B Paterson; M A Caligiuri; J E Dick
Journal:  Nature       Date:  1994-02-17       Impact factor: 49.962

8.  Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia.

Authors:  Elwin J C Rombouts; Biljana Pavic; Bob Löwenberg; Rob E Ploemacher
Journal:  Blood       Date:  2004-03-30       Impact factor: 22.113

9.  Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.

Authors:  David C Taussig; Farideh Miraki-Moud; Fernando Anjos-Afonso; Daniel J Pearce; Kirsty Allen; Christopher Ridler; Debra Lillington; Heather Oakervee; Jamie Cavenagh; Samir G Agrawal; T Andrew Lister; John G Gribben; Dominique Bonnet
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

10.  Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

View more
  1 in total

1.  Unsupervised discovery of dynamic cell phenotypic states from transmitted light movies.

Authors:  Phuc Nguyen; Sylvia Chien; Jin Dai; Raymond J Monnat; Pamela S Becker; Hao Yuan Kueh
Journal:  PLoS Comput Biol       Date:  2021-12-30       Impact factor: 4.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.